Advanced Search
REVIEW ARTICLE
Korean J Pediatr 2011 April;54(4) :146-151.
doi:https://doi.org/10.3345/kjp.2011.54.4.146
Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
Eun Hwa Choi (Choi EH), Kyung Hyo Kim (Kim KH), Yae Jean Kim (Kim YJ), Jong Hyun Kim (Kim JH), Su Eun Park (Park SE), Hoan Jong Lee (Lee HJ), Byung Wook Eun (Eun BW), Dae Sun Jo (Jo DS), Kyong Min Choi (Choi KM), Young Jin Hong (Hong YJ)
The Committee on Infectious Diseases, the Korean Pediatric Society
Corresponding Author: Eun Hwa Choi ,Tel: +82.2-2072-3624, Fax: 82.2-766-7283, Email: eunchoi@snu.ac.kr
Copyright © 2011 by The Korean Pediatric Society
ABSTRACT
Streptococcus pneumoniae remains a leading cause of invasive infections including bacteremia and meningitis, as well as mucosal infections such as otitis media and pneumonia among children and adults. The 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among infants and young children in many countries including Korea. The routine use of PCV7 has resulted in a decreased incidence of invasive pneumococcal disease (IPD) by the vaccine serotypes among the vaccinees and substantial declines in IPD among unvaccinated populations such as older children and adults as well. In addition, there are increasing evidences to suggest that routine immunization with PCV7 is changing the epidemiology of pneumococcal diseases such as serotype distribution of IPD, nasopharyngeal colonization, and antibiotic resistance patterns. In contrast, there is an increase in the number of IPDs caused by nonvaccine serotypes, though it is much smaller than overall declines of vaccine serotype diseases. Several vaccines containing additional serotypes have been developed and tested clinically in order to expand the range of serotypes of Streptococcus pneumoniae. Recently two new pneumococcal protein conjugate vaccines, 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13), have been approved for use in several countries including Korea. This report summarizes the recommendations approved by the Committee on Infectious Diseases, the Korean Pediatric Society.
Keywords: Streptococcus pneumoniae | Pneumococcal conjugate vaccine | Serotype
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
  via Pubmed
Full text via PMC  Full text via PMC
via Pubreader  via PubReader
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
1,219
View
5
Download
Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines  2014 February;57(2)
Recommendation for the use of newly introduced Tdap vaccine in Korea  2011 April;54(4)
Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children  2008 June;51(6)
Efficacy and effectiveness of pneumococcal conjugate vaccine in children  2006 March;49(3)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.